309 related articles for article (PubMed ID: 31711435)
41. Organized primary human papillomavirus-based cervical screening: A randomized healthcare policy trial.
Elfström KM; Eklund C; Lamin H; Öhman D; Hortlund M; Elfgren K; Sundström K; Dillner J
PLoS Med; 2021 Aug; 18(8):e1003748. PubMed ID: 34424907
[TBL] [Abstract][Full Text] [Related]
42. An on-going study of three different cervical cancer screening strategies based on primary healthcare facilities in Beijing China.
Han L; Chang X; Song P; Gao L; Zhang Y; An L; Shen J
J Infect Public Health; 2020 Apr; 13(4):577-583. PubMed ID: 31564529
[TBL] [Abstract][Full Text] [Related]
43. Application of the Cobas 4800 System for the Detection of High-Risk Human Papillomavirus in 5650 Asymptomatic Women.
Wang S; He X; Meng F; Pan Q; Zhang L; Zeng J
Biomed Res Int; 2020; 2020():1635324. PubMed ID: 32280677
[TBL] [Abstract][Full Text] [Related]
44. Variation in cervical cancer screening test utilization and results in a United States-based program.
Dorismond VG; Saraiya M; Gopalani SV; Soman A; Kenney K; Miller J; Sawaya GF
Gynecol Oncol; 2024 May; 184():96-102. PubMed ID: 38301312
[TBL] [Abstract][Full Text] [Related]
45. Previous cervical cytology and high-risk human papillomavirus testing in a cohort of patients with invasive cervical carcinoma in Shandong Province, China.
Zhang L; Xie F; Wang X; Peng D; Bi C; Jiang L; Zhao D; Tian X; Qi D
PLoS One; 2017; 12(6):e0180618. PubMed ID: 28662160
[TBL] [Abstract][Full Text] [Related]
46. An economic evaluation of two cervical screening algorithms in Belgium: HR-HPV primary compared to HR-HPV and liquid-based cytology co-testing.
Dombrowski C; Bourgain C; Ma Y; Meiwald A; Pinsent A; Weynand B; Turner KME; Huntington S; Adams EJ; Bogers J; Croes R; Sahebali S
Eur J Cancer Prev; 2024 May; 33(3):262-270. PubMed ID: 37933867
[TBL] [Abstract][Full Text] [Related]
47. Dried cervical spots for human papillomaviruses identification.
Charbonneau V; Garrigue I; Jaquet A; Horo A; Minga A; Recordon-Pinson P; Dabis F; Fleury H
J Med Virol; 2013 Jul; 85(7):1222-8. PubMed ID: 23595602
[TBL] [Abstract][Full Text] [Related]
48. HPV genotypes in high grade cervical lesions and invasive cervical carcinoma as detected by two commercial DNA assays, North Carolina, 2001-2006.
Hariri S; Steinau M; Rinas A; Gargano JW; Ludema C; Unger ER; Carter AL; Grant KL; Bamberg M; McDermott JE; Markowitz LE; Brewer NT; Smith JS
PLoS One; 2012; 7(3):e34044. PubMed ID: 22479516
[TBL] [Abstract][Full Text] [Related]
49. Evaluation of the performance of Human Papillomavirus testing in paired urine and clinician-collected cervical samples among women aged over 30 years in Bhutan.
Tshomo U; Franceschi S; Tshokey T; Tobgay T; Baussano I; Tenet V; Snijders PJ; Gheit T; Tommasino M; Vorsters A; Clifford GM
Virol J; 2017 Apr; 14(1):74. PubMed ID: 28390433
[TBL] [Abstract][Full Text] [Related]
50. Retrospective analysis of negative cytology results correlated with a positive high-risk in the human papillomavirus result and subsequent results of patients over a period of three years.
Piotrowski PG; Jeleń MT
Pol J Pathol; 2024; 75(1):36-39. PubMed ID: 38741427
[TBL] [Abstract][Full Text] [Related]
51. Screening for Cervical Cancer: US Preventive Services Task Force Recommendation Statement.
; Curry SJ; Krist AH; Owens DK; Barry MJ; Caughey AB; Davidson KW; Doubeni CA; Epling JW; Kemper AR; Kubik M; Landefeld CS; Mangione CM; Phipps MG; Silverstein M; Simon MA; Tseng CW; Wong JB
JAMA; 2018 Aug; 320(7):674-686. PubMed ID: 30140884
[TBL] [Abstract][Full Text] [Related]
52. Impact of Screening Modality on the Detection of Cervical Adenocarcinoma In Situ and Adenocarcinoma.
Zhang RC; Vue NC; Obasi LU; Vogel RI; Subramanian AT; Khalifa MA; Reddy BR; Erickson BK
J Low Genit Tract Dis; 2021 Oct; 25(4):267-269. PubMed ID: 34265818
[TBL] [Abstract][Full Text] [Related]
53. Polymerase Chain Reaction Human Papillomavirus (HPV) Detection and HPV Genotyping in Invasive Cervical Cancers With Prior Negative HC2 Test Results.
Tao X; Zheng B; Yin F; Zeng Z; Li Z; Griffith CC; Luo B; Ding X; Zhou X; Zhao C
Am J Clin Pathol; 2017 May; 147(5):477-483. PubMed ID: 28340235
[TBL] [Abstract][Full Text] [Related]
54. Cytology, High-Risk Human Papillomavirus Testing and Serum CA19-9 in a Large Cohort of Patients with Invasive Cervical Adenocarcinomas: Correlation with a New Pathogenetic Classification.
Shi H; Ma Y; Shao Y; Zhang Y; Lu B
Asian Pac J Cancer Prev; 2022 Aug; 23(8):2599-2605. PubMed ID: 36037112
[TBL] [Abstract][Full Text] [Related]
55. Moving forward-the 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors and beyond: implications and suggestions for laboratories.
Nayar R; Chhieng DC; Crothers B; Darragh TM; Davey DD; Eisenhut C; Goulart R; Huang EC; Tabbara SO
J Am Soc Cytopathol; 2020; 9(4):291-303. PubMed ID: 32565297
[TBL] [Abstract][Full Text] [Related]
56. Molecular and pathological basis of HPV-negative cervical adenocarcinoma seen in a global study.
Jenkins D; Molijn A; Kazem S; Pirog EC; Alemany L; de Sanjosé S; Dinjens W; Quint W
Int J Cancer; 2020 Nov; 147(9):2526-2536. PubMed ID: 32474915
[TBL] [Abstract][Full Text] [Related]
57. By how much could screening by primary human papillomavirus testing reduce cervical cancer incidence in England?
Castanon A; Landy R; Sasieni P
J Med Screen; 2017 Jun; 24(2):110-112. PubMed ID: 27363972
[TBL] [Abstract][Full Text] [Related]
58. HPV testing for cervical cancer screening: technical improvement of laboratory logistics and good clinical performance of the cobas 6800 in comparison to the 4800 system.
Frayle H; Gori S; Rizzi M; Graziani BN; Vian E; Giorgi Rossi P; Del Mistro A
BMC Womens Health; 2019 Mar; 19(1):47. PubMed ID: 30909894
[TBL] [Abstract][Full Text] [Related]
59. Recall Efforts Successfully Increase Follow-Up for Cervical Cancer Screening Among Women With Human Papillomavirus in Honduras.
Thomson KA; Sandoval M; Bain C; Holme F; Bansil P; Figueroa J; de Sanjosé S
Glob Health Sci Pract; 2020 Jun; 8(2):290-299. PubMed ID: 32606095
[TBL] [Abstract][Full Text] [Related]
60. Acceptability and Preferences of Dry HR HPV Self-Sampling Mailed Kits Among Canadian Women: A Cross-Sectional Study.
Ruel-Laliberté J; Jacob-Wagner M; Bestman-Smith J; Paré J
J Obstet Gynaecol Can; 2023 Apr; 45(4):261-266. PubMed ID: 36870436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
